Back to Search Start Over

EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells

Authors :
Karina Alexandre Barros Nogueira
Felipe Tita de Lima
Júlio César Borges
Juliana Maldonado Marchetti
Carlos Sabino de Oliveira
Raquel Petrilli
Marlus Chorilli
Wafa' T Al-Jamal
Elias da Silva Santos
Amalia Ruiz
Josimar O. Eloy
Giovanni Loureiro Raspantini
Dentistry and Nursing
Queen's University Belfast
Universidade Estadual Paulista (Unesp)
Institute of Health Sciences
Universidade de São Paulo (USP)
Source :
Scopus, Repositório Institucional da UNESP, Universidade Estadual Paulista (UNESP), instacron:UNESP, Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual), Universidade de São Paulo (USP), instacron:USP, Eloy, J O, Ruiz, A, de Lima, F T, Petrilli, R, Raspantini, G, Nogueira, K A B, Santos, E, de Oliveira, C S, Borges, J C, Marchetti, J M, Al-Jamal, W T & Chorilli, M 2020, ' EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells ', Colloids and Surfaces B: Biointerfaces, vol. 194, 111185 . https://doi.org/10.1016/j.colsurfb.2020.111185
Publication Year :
2020

Abstract

Made available in DSpace on 2020-12-12T02:11:22Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-10-01 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Prostate cancer is the second cause of cancer death in men worldwide. Docetaxel (DTX), an antimitotic drug, is widely used for the treatment of metastatic prostate cancer patients. Taxotere® is a commercial DTX formulation. It contains a polysorbate 80 surfactant to improve DTX aqueous solubility, which has been associated with hypersensitivity reactions in patients. Liposomes have been used as promising delivery systems for a range of hydrophobic drugs, such as DTX, offering improved drug water solubility and biocompatibility, without compromising its anticancer activity. Herein, DTX-loaded liposomes were developed using the Box-Behnken factorial design. The optimized formulation was nano-sized, homogenous in size (67.47 nm) with high DTX encapsulation efficiency (99.95 %). The encapsulated DTX was in a soluble amorphous state, which was slowly released. Next, to increase the liposomes selectivity to prostate cancer cells, cetuximab, an anti-EGFR monoclonal antibody. was successfully conjugated to the surface of liposomes, without compromising cetuximab protein structure and stability. As expected, our results showed higher cellular uptake and toxicity of immunoliposomes, compared to non-targeted liposomes, in DU145 (EGFR-overxpressing) prostate cancer cells. To the best of our knowledge, this is the first report of engineering EGFR-targeted liposomes to enhance the selectivity of DTX delivery to EGFR-positive prostate cancer cells. Federal University of Ceará College of Pharmacy Dentistry and Nursing Department of Pharmacy School of Pharmacy Queen's University Belfast, 97 Lisburn Rd School of Pharmaceutical Sciences of Araraquara São Paulo State University UNESP Department of Drugs and Medicines University for International Integration of the Afro-Brazilian Lusophony Institute of Health Sciences College of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo São Carlos Institute of Chemistry University of São Paulo School of Pharmaceutical Sciences of Araraquara São Paulo State University UNESP Department of Drugs and Medicines

Details

ISSN :
18734367
Volume :
194
Database :
OpenAIRE
Journal :
Colloids and surfaces. B, Biointerfaces
Accession number :
edsair.doi.dedup.....6d4bcc57eba7ab680aaffa40ec7c4594
Full Text :
https://doi.org/10.1016/j.colsurfb.2020.111185